{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "RVTY",
  "name": "Revvity, Inc.",
  "url": "https://frontierpicks.com/dossiers/RVTY/",
  "json_url": "https://frontierpicks.com/dossiers/RVTY.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a3",
    "n": 3
  },
  "current_thesis": "Post-2026-08-04 print, RVTY re-rated on the wet-lab-under-AI story — management's strongest instrument backlog in 3–4 years — plus Diagnostics +11% organic and a signed exit from China immunodiagnostics. KeyBanc took its target to $165 on 09-04 while RBC initiated at $135 on 09-01, and the next number-bearing event is the late-October Q3 print, leaving the shares at a 52-week high with only conference appearances in between.",
  "invalidation_trigger": "A weekly close below $116 (loses the 50-day average at $116.40 and the entire post-2026-08-04 advance), or a Q3 print in late October that trims FY26 organic growth back toward 3–4% with Life Sciences still contracting.",
  "catalyst_date": "2026-09-09",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics",
    "ai-datacenter-infrastructure"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "China immunodiagnostics (~6% of FY2025 revenue) stays consolidated until the divestiture closes, expected end of 2027.",
    "Roughly half the revenue base is Diagnostics and half Life Sciences; the two segments moved in opposite directions in Q2 2026.",
    "Short interest was 6.26% of float on 111.59M shares outstanding (stockanalysis.com, 2026-09-05) — elevated for a large-cap tools name.",
    "pre-2023 comparables are not like-for-like."
  ],
  "body_markdown": "## Current Thesis\n\nThe leg being bought is the wet-lab layer underneath AI drug discovery. On the 2026-08-04 Q2 call, management said instrumentation backlog was the strongest in three to four years and credited demand from AI-driven drug discovery customers — the argument being that generated hypotheses still have to be tested with reagents, instruments and biological data. That claim landed on top of a Diagnostics segment growing 11% organically and a signed exit from the structurally impaired China immunodiagnostics business. The narrative is accelerating: the re-rate is only weeks old, RBC opened new coverage on 2026-09-01 and KeyBanc raised its target to $165 on 2026-09-04, and the shares closed 2026-09-04 at $130.22, 0.5% under the $130.94 52-week high after a three-month price change of +29.9%.\n\nThe qualifier sits in the same evidence: RBC's initiation carries a $135 target against that $130.22 close, which is the first dated marker of an analyst arriving at the story and finding it already priced.\n\n## Bull Case\n\n- **Q2 2026 print, 2026-08-04:** revenue $711M, pro forma organic growth +3%, adjusted EPS $1.41 versus the $1.21 consensus cited in post-print coverage, adjusted operating margin 29.3%.\n- **Guidance raised the same day:** FY26 organic growth to 4–5% from 3–4%, adjusted EPS to $5.30–$5.40 (up $0.10), revenue $2.83–$2.86B, adjusted operating margin ~28.7%.\n- **Diagnostics is carrying the model:** $352M revenue, +11% organic in Q2, with Reproductive Health up mid-teens organically and immunodiagnostics ex-China accelerating to high single digits.\n- **Backlog claim, Q2 call 2026-08-04:** strongest instrumentation backlog in three to four years. This is the load-bearing number for the whole AI-adjacent framing, and it is management-sourced rather than independently observable.\n- **Portfolio surgery:** definitive agreement to divest the China immunodiagnostics business, roughly 6% of FY2025 revenue, cited by management as a persistent policy-headwind and low-return line. Closing expected by end of 2027.\n- **Leverage came down:** a EUR 500M bond was repaid in July 2026, taking net debt/EBITDA to 2.5x.\n- **Sell-side momentum:** KeyBanc maintained Overweight and raised its target to $165 on 2026-09-04.\n\n## Bear Case\n\n- **Half the company shrank in Q2:** Life Sciences revenue $359M, organic -3%, with the software line down approximately double digits per coverage of the Q2 slide deck. The AI-validation story is being told over a segment that is currently contracting.\n- **The guide requires acceleration:** organic growth printed +3% in Q2 against a full-year 4–5% frame, so the second half has to do the work.\n- **Valuation carries the beat:** forward P/E of 23.05 (stockanalysis.com, 2026-09-05) on a mid-single-digit organic grower whose margin guide is ~28.7%.\n- **The marginal analyst is neutral:** RBC initiated Sector Perform on 2026-09-01 with a $135 target — barely above the last close, not a re-rate call.\n- **The divestiture is slow:** China immunodiagnostics stays consolidated until a close expected by end of 2027, leaving policy and execution exposure inside the reported numbers for five-plus quarters.\n- **No company-dated event inside 30 days changes a number.** Three conference appearances between 2026-09-09 and 2026-09-15 are fireside chats, not order-book disclosures; the next print that can confirm or break the backlog claim is the Q3 report expected in late October.\n\n## Setup & Price Structure\n\n- Last completed daily close 2026-09-04 at $130.22, against a 52-week high of $130.94 — 0.5% below it. RSI(14) reads 73.4.\n- The 50-day moving average sits at $116.40 and the 200-day at $102.36 (stockanalysis.com, 2026-09-05). Both slope up; price sits well clear of each, which is what a +29.9% three-month move produces and also what leaves no shelf directly under the tape.\n- No consolidation has formed since the 2026-08-04 gap. The first structural level beneath the market is the 50-day at $116.40; below that, the post-print advance is gone entirely.\n- **Crowding observables, stated as observables:** RSI(14) 73.4 with the close 0.5% off the 52-week high; short interest 6.42M shares, 6.26% of float, on 111.59M shares outstanding (stockanalysis.com, 2026-09-05); fresh sell-side attention inside seven days (new coverage 09-01, target raise 09-04); target dispersion of $135 to $165 straddling a $130.22 close. The filing feed reviewed for this note shows no recent insider transactions — that is an absence in one feed, not proof that none occurred.\n- What the structure does not offer is a defined-risk entry shelf: the nearest one sits back at the 50-day, so anything bought at the highs is underwritten by the Q3 print rather than by the chart.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-09** — Wells Fargo 21st Annual Healthcare Conference, 8:45 a.m. ET, CEO Prahlad Singh. First public management commentary since the 08-04 print; the backlog claim either gets repeated with detail or it does not.\n- **2026-09-14** — Morgan Stanley 24th Annual Global Healthcare Conference, 8:30 a.m. ET, CFO Max Krakowiak. Margin path to ~28.7% and the China divestiture timeline are the CFO-level questions.\n- **2026-09-15** — Baird 2026 Global Healthcare Conference, 9:05 a.m. ET, SVP Steve Willoughby.\n- **~2026-10-27 (est.)** — Q3 2026 results. Outside the 30-day window and the only event that can put a number against the instrument-backlog narrative. Date unconfirmed; the Q2 report came 2026-08-04 before market open.\n\n## What Would Change Our Mind\n\nThe fundamental break comes first. The backlog claim is management-sourced and unverifiable until it converts: a Q3 print (expected late October) that leaves Life Sciences organic growth negative, trims FY26 organic growth back toward 3–4%, or discloses no follow-through on instrument orders would remove the reason the multiple expanded in August. A second, quieter break: the three September conference appearances passing without incremental order-book or backlog detail while the shares remain pinned against $130.94 — that is the shape of the story going saturated as coverage arrives without a widening bid.\n\nOn the tape, a weekly close below $116 loses the 50-day average at $116.40 and gives back the entire post-08-04 advance; that condition ends the re-rate leg regardless of what the guidance says.\n\nThe opposite datapoint also exists: sustained weekly closes above $135 — RBC's initiation target — with Q3 confirming instrument conversion would say the neutral incremental analyst was early rather than right.\n\n## Correlation Notes\n\n- No theme cluster in the current registry carries this name, so this is a single-name read and nothing here leans on a group move.\n- The natural comparable set is Thermo Fisher, Danaher, Agilent and Bruker; shared drivers are pharma and biotech R&D budgets, NIH and academic funding, instrument tariffs and China demand policy. A funding or capex headline that hits the group hits this name whatever the backlog says.\n- Five-year beta is 1.09 (stockanalysis.com, 2026-09-05) — this does not trade as a defensive.\n- Internally the two halves decouple: Reproductive Health and newborn screening track birth rates and screening-panel adoption, not the instrument cycle, which is why Diagnostics printed +11% organic in Q2 while Life Sciences printed -3%.\n- Once the China immunodiagnostics divestiture closes (expected end of 2027, per the 2026-08-04 disclosure), roughly 6% of FY2025 revenue and its associated China policy sensitivity leave the reported base — a structural change in the name's correlation profile, not a near-term one.",
  "first_seen": "2026-09-04",
  "last_analyzed": "2026-09-06T08:07:55+00:00",
  "last_synthesized": "2026-09-05",
  "last_update_source": "research_universe",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}